- Home
- AENT vs AQST Comparison
AENT vs AQST Comparison
Compare AENT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- AQST
- Stock Information
- Founded
- AENT 1990
- AQST 2004
- Country
- AENT United States
- AQST United States
- Employees
- AENT N/A
- AQST N/A
- Industry
- AENT Durable Goods
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- AQST Health Care
- Exchange
- AENT Nasdaq
- AQST Nasdaq
- Market Cap
- AENT 290.3M
- AQST 274.4M
- IPO Year
- AENT N/A
- AQST 2018
- Fundamental
- Price
- AENT $3.65
- AQST $2.75
- Analyst Decision
- AENT
- AQST Strong Buy
- Analyst Count
- AENT 0
- AQST 7
- Target Price
- AENT N/A
- AQST $10.57
- AVG Volume (30 Days)
- AENT 76.1K
- AQST 1.5M
- Earning Date
- AENT 05-08-2025
- AQST 03-05-2025
- Dividend Yield
- AENT N/A
- AQST N/A
- EPS Growth
- AENT N/A
- AQST N/A
- EPS
- AENT 0.13
- AQST N/A
- Revenue
- AENT $1,070,804,000.00
- AQST $57,561,000.00
- Revenue This Year
- AENT $4.77
- AQST N/A
- Revenue Next Year
- AENT N/A
- AQST $35.72
- P/E Ratio
- AENT $28.22
- AQST N/A
- Revenue Growth
- AENT N/A
- AQST 13.80
- 52 Week Low
- AENT $1.10
- AQST $2.24
- 52 Week High
- AENT $11.57
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- AENT 40.95
- AQST 45.85
- Support Level
- AENT $3.17
- AQST $2.45
- Resistance Level
- AENT $3.85
- AQST $2.91
- Average True Range (ATR)
- AENT 0.45
- AQST 0.20
- MACD
- AENT 0.03
- AQST 0.03
- Stochastic Oscillator
- AENT 32.28
- AQST 49.18
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.